Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Oculis completed randomization of 176 patients in PREDICT-1, its genotype-based registrational trial of Licaminlimab for TNFR1-mediated dry eye disease. Two-thirds of enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced response in Phase 2, and topline data are expected around year-end 2026. If successful, Licaminlimab would be a first-in-class precision medicine for an estimated 1.5+ million U.S.
Key figures
- Drug Name
- Licaminlimab
- Phase Of Trial
- registrational (Phase 3-equivalent, PREDICT-1)
- Patients enrolled
- 176
- Topline data timing
- around year-end 2026
- Tnfr1 genotype share
- 2/3 of enrolled patients
- Addressable patients us
- 1.3-1.9 million (1.5+ million estimated)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.